Compare MGM Resorts International (MGM) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Organon & Co. Common Stock — how do they compare? MGM Resorts International trades at $28.73 (market cap $7.40B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: MGM Resorts International is far larger — about 2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 92 Days and Organon & Co. Common Stock for 0 Days on average.
| MGM | OGN | |
|---|---|---|
Market Cap | $7.40B | $3.62B |
Volume | 3,687,296 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $13.81 |
52-Week Low | $28.96 | $5.70 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $34.70B | $11.04B |
Dividend Yield | 0.03% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $28.96, down 1.23% amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition offer. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal mixed results with Q2 2026 EPS beating expectations but net margins declining to 2.4%. Recent news highlights ongoing M&A discussions, including potential MGM bids for People Inc., creating uncertainty around strategic direction.
Despite near-term headwinds, MGM maintains strong analyst support with 51% buy ratings and a $47.57 consensus target representing 64% upside. Key risks include execution on acquisition strategy, declining profitability margins, and high debt levels. The current valuation at 17.8x P/E appears reasonable if management can stabilize earnings and navigate the evolving casino landscape effectively.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
